Toth Financial Advisory Corp Has $77,000 Stock Position in Ascendis Pharma A/S $ASND

Key Points

• Toth Financial Advisory Corp significantly reduced its ownership in Ascendis Pharma A/S, selling 4,890 shares, which decreased its stake by 91.7% in the second quarter.
• Ascendis Pharma A/S reported a loss of $0.93 earnings per share for the last quarter, surpassing analysts' expectations, with revenues of $216.28 million compared to a projected $163.17 million.
• Multiple analysts have issued positive ratings for Ascendis Pharma A/S, with target price increases up to $295.00 from firms like Wells Fargo & Company, indicating a strong market interest in the stock.

Toth Financial Advisory Corp cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 91.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 445 shares of the biotechnology company's stock after selling 4,890 shares during the period. Toth Financial Advisory Corp's holdings in Ascendis Pharma A/S were worth $77,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ASND. GF Fund Management CO. LTD. purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $174,000. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 15,593.0% in the first quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company's stock worth $142,600,000 after purchasing an additional 90,907 shares during the period. Harbor Capital Advisors Inc. raised its stake in shares of Ascendis Pharma A/S by 1.3% during the first quarter. Harbor Capital Advisors Inc. now owns 85,960 shares of the biotechnology company's stock valued at $13,398,000 after purchasing an additional 1,087 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in Ascendis Pharma A/S in the 1st quarter worth about $226,000. Finally, Diversified Trust Co grew its stake in shares of Ascendis Pharma A/S by 3.4% in the 1st quarter. Diversified Trust Co now owns 46,548 shares of the biotechnology company's stock valued at $7,255,000 after buying an additional 1,510 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of ASND traded down $1.26 during midday trading on Monday, hitting $196.42. 1,061,775 shares of the stock traded hands, compared to its average volume of 360,198. Ascendis Pharma A/S has a 1-year low of $118.03 and a 1-year high of $208.16. The firm has a market capitalization of $12.10 billion, a PE ratio of -38.07 and a beta of 0.39. The business's 50 day moving average price is $188.13 and its two-hundred day moving average price is $171.63.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analyst estimates of $163.17 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ASND shares. UBS Group reiterated a "buy" rating and set a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Wall Street Zen lowered shares of Ascendis Pharma A/S from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Royal Bank Of Canada upped their target price on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a report on Tuesday, August 19th. Fifteen investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and an average target price of $244.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.